Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
ISSN: 2155-9570
Virginia Vanzzini-Zago, Maritza Omana-Molina, Marino Alcantara-Castro, Victor Flores-Alvarado and Dalia Rojo
Hospital Dr. Luis Sanchez Bulnes, Mexico
Autonomous University of Mexico, Mexico
Posters & Accepted Abstracts: J Clin Exp Ophthalmol
Introduction: Nowadays there is not a specific and satisfactory treatment for Acanthamoeba keratitis (AK). Aminoglycosides (neomicin) was the first drug used in the medical AK treatment, imidazoles and triazoles (itraconazole) associated to debridement are used too for the treatment in the decade of 80. Objective: The description of a gentle, low cost medical treatment available in Mexico for AK in cases with an early diagnosis. Material & Methods: We will describe two cases of early clinical and culture proven diagnosed AK, in two young females, in one case with the infection in both corneas (three eyes in total), treated with topic droops of netilmicin 0.3% (Netira SCIFI Laboratory Italy), two drops each two hours, during 48 hours (day and night) and itraconazole (Nizoral Jenssen laboratory, Netherlands) by mouth 200 mgs/24 hours/15-30 days. After the first 48 hours, the droops of netilmicin can be administered 4 times a day, for the time as was needed until the healed cornea was achieved (3 to 4 months). Results: The 3 Acanthamoeba strains was obtained in cornea scrap cultures and identified as, Acanthamoeba royreba (T4) in case 1 and Acanthamoeba castellanii in case 2 the Acanthamoeba cultures where made in NNA with a layer of live Enterobacter aerogenes. Conclusion: In countries where the classic drugs are not suggested for the treatment of AK, there is a need to look for other alternatives in the medical treatment.
Virginia Vanzzini-Zago is recently working in Autonomous University of Mexico, Mexico.